Caitlin Breitenbruck focuses primarily on mergers and acquisitions and other complex corporate transactions. Her clients include strategic and financial buyers and sellers in public and private acquisitions.
Principia Biopharma Agrees to Sell to Sanofi for Approximately $3.68 Billion
August 18, 2020
Cooley advised Principia Biopharma on its agreement to sell all outstanding shares to Sanofi for $100 per share, representing an aggregate equity value of approximately $3.68 billion. Jamie Leigh, Ben Beerle, David Peinsipp and Anne Lieberman led the Cooley team advising Principia.
Cornerstone OnDemand Agrees to Buy Saba for Nearly $1.4 Billion
February 25, 2020
Cooley advised Cornerstone OnDemand, a global leader in people development solutions, on its agreement to acquire talent solution company Saba for approximately $1.395 billion in cash and stock. Lawyers Ben Beerle, Rachel Proffitt and Anne Lieberman led the Cooley team advising Cornerstone on the transaction, which is expected to close in Q2, and Mischi a Marca, Patrick Flanagan and McLean Crichton advised Cornerstone on the debt financing for the transaction.
Thoma Bravo’s Instructure Agrees to Sell Employee Development Platform Bridge to Learning Technologies Group
March 3, 2021
Cooley advised Instructure, a Thoma Bravo-owned education technology company, on its agreement to sell Bridge, an employee learning, performance and skills development platform, to Learning Technologies Group. Lawyers Matt Hemington, David Silverman, Anna Maria Galinska, Caitlin Breitenbruck and Steve Tonsfeldt led the Cooley team advising Instructure.
Cooley advised ShipMonk, a provider of ecommerce fulfillment and technology solutions, on its $290 million growth equity round backed by Summit Partners. The financing represents a minority stake in the business and will help further accelerate ShipMonk’s rapid growth through continued investment in research and development, hiring, the development of B2B fulfillment capabilities and international expansion. Partner Dave Young led the team advising ShipMonk.
Cooley advised Alkahest, a Silicon Valley-based biopharma company, on its agreement to sell its remaining stake to Grifols, a producer of plasma therapies, for $146 million. The deal will add a range of new products to Grifols' discovery and development pipeline, which will help roll out new therapeutic medicines to market. Alkahest is a clinical stage company that is focused on the discovery and development of treatments for neurodegenerative and age-related diseases with therapies that target the aging plasma proteome. Lawyers Seth Gottlieb and Anne Lieberman led the Cooley team advising Alkahest.